Stocks · News reference
Quantum Biopharma shares are trading higher after the company announced it received FDA approval to proceed with its Lucid-MS Phase 2 clinical trial in progressive multiple sclerosis.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 6:37 PM
- Checked
- Aug 14, 2026, 6:37 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial
FDA approves Quantum BioPharma's IND application for Lucid-MS, advancing its progressive multiple sclerosis treatment to Phase 2 trials.
Read original at benzingaEXCLUSIVE: FDA Approves Quantum BioPharma's Lucid-MS Phase 2 Trial of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination For Progressive Multiple Sclerosis
Read original at benzinga